UCB SA (OTCMKTS:UCBJY) Short Interest Up 363.3% in February

UCB SA (OTCMKTS:UCBJY) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 13,900 shares, an increase of 363.3% from the February 13th total of 3,000 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily volume of 92,400 shares, the days-to-cover ratio is currently 0.2 days.

UCB Stock Up 6.1 %

OTCMKTS:UCBJY opened at $98.50 on Thursday. UCB has a one year low of $56.77 and a one year high of $106.60. The firm’s fifty day moving average price is $97.55 and its two-hundred day moving average price is $95.25. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.